Marex Group’s Sage Therapeutics SAGE Stock Holding History

Marex Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,814	Closed	-$454K	–	291
2023 Q1	$454K	Buy	10,814 +3,101	+40%	+$133K	0.06%	166
2022 Q4	$294K	Buy	+7,713	New	+$295K	0.04%	202

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marex Group's SAGE Position: Q2 2023 in Review

Marex Group sold out of Sage Therapeutics (SAGE) in Q2 2023, closing a stake of 10,814 shares — an estimated $454K sold.

Marex Group first reported a position in SAGE in Q4 2022 and held it in 2 quarters. The position peaked at $454K in Q1 2023. 225 funds tracked by Wall St. Rank hold SAGE as of Q2 2023.

Marex Group reported no remaining Sage Therapeutics position as of Q2 2023 after selling out during the quarter.
Marex Group sold 10,814 Sage Therapeutics shares in Q2 2023, an estimated $454K.
Marex Group first reported a position in Sage Therapeutics in Q4 2022 and held it in 2 quarters.
Marex Group's Sage Therapeutics position peaked at $454K in Q1 2023.
225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2023.

Based on Marex Group's 13F filing for Q2 2023, filed 2 Apr 2026.